QuantaMatrix Incorporated
Established in 2010, listed on KOSDAQ in 2020, QuantaMatrix develops dRAST and QDST antimicrobial susceptibility testing systems.
As of 2026-10-11, QuantaMatrix Incorporated has 30 Korean MFDS device approvals, 24 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureQuantaMatrix Incorporated was established on November 29, 2010 and listed on KOSDAQ on December 9, 2020 as an in vitro diagnostics (IVD) medical device company. Based on microbial diagnostic technology, it develops and produces the dRAST automated rapid antimicrobial susceptibility testing system with dRAST GN S17 and GP S17 test kits, and the QDST automated rapid anti-tuberculosis susceptibility testing system with the QMAC-DST13 test kit. The company researches, manufactures, and sells these in vitro diagnostic devices for tertiary general hospitals and reference laboratories in Korea and abroad, and is also pursuing commercialization of medical devices for early disease diagnosis and prognosis prediction based on its own molecular immunodiagnostic testing platform.
Products & technology
- dRASTAutomated rapid antimicrobial susceptibility testing system
- dRAST GN S17 / GP S17Rapid antimicrobial susceptibility test kit
- QDSTAutomated rapid anti-tuberculosis susceptibility testing system
- QMAC-DST13Rapid anti-tuberculosis susceptibility test kit
Regulatory approvals
data.go.kr30 Korean MFDS device approvals · 2014–2026
- MFDSMicrobial susceptibility testing analyzer2026-01-20Product approval · Class 1체외 제신 26-77 호
- MFDSMicrobial identification analyzer2022-09-28Product approval · Class 1체외 수신 22-1645 호
- MFDSMicrobial identification analyzer2022-09-21Product approval · Class 1체외 수신 22-1611 호
- MFDSIVD reagents and media for antibiotic susceptibility2022-04-13Product approval · Class 2체외 제인 22-4292 호
- MFDSIVD reagents for general immune test2021-11-04Product approval · Class 2체외 제인 21-4937 호
- MFDSIVD reagents for staining or culturing clinical microbiology2021-07-23Product approval · Class 1체외 제신 21-1019 호
- MFDSIVD reagents and media for antibiotic susceptibility2021-06-18Product approval · Class 2체외 제인 21-4533 호
- MFDSIVD reagents and media for antibiotic susceptibilityRevoked2021-06-18Product approval · Class 2체외 제인 21-4532 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2021-05-06Product approval · Class 3체외 제허 21-353 호
- MFDSIVD reagents and media for antibiotic susceptibility2021-02-23Product approval · Class 2체외 제인 21-4144 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-09-24Product approval · Class 3체외 제허 20-838 호
- MFDSIVD reagents for general immune test2020-07-20Product approval · Class 2체외 제허 20-589 호
Show 18 more
- MFDSIVD reagents for general immune testRevoked2020-06-02Product approval · Class 2체외 제허 20-430 호
- MFDSFluorometer for clinical use2020-01-06Product approval · Class 1체외 제신 20-15 호
- MFDSIVD reagents and media for antibiotic susceptibility2018-06-05Product approval · Class 2체외 제인 18-4422 호
- MFDSIVD reagents and media for antibiotic susceptibility2018-03-30Product approval · Class 2체외 제인 18-4248 호
- MFDSIVD reagents and media for antibiotic susceptibility2018-02-05Product approval · Class 2체외 제인 18-4086 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2018-01-08Product approval · Class 3체외 제허 18-11 호
- MFDSIVD reagents for inflammatory testsRevoked2017-12-19Product approval · Class 2체외 제인 17-4985 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2017-11-15Product approval · Class 3체외 제허 17-872 호
- MFDSFluorometer for clinical useRevoked2017-11-09Product approval · Class 1체외 제신 17-1291 호
- MFDSFluorometer for clinical useRevoked2017-08-25Product approval · Class 1체외 제신 17-988 호
- MFDSMicrobial susceptibility testing analyzer2016-08-01Product approval · Class 1체외 제신 16-936 호
- MFDSIVD reagents and media for antibiotic susceptibilityRevoked2016-06-21Product approval · Class 2체외 제허 16-440 호
- MFDSIVD reagents and media for antibiotic susceptibilityRevoked2016-06-21Product approval · Class 2체외 제인 16-441 호
- MFDSIVD reagents and media for antibiotic susceptibilityRevoked2016-06-03Product approval · Class 2체외 제허 16-399 호
- MFDSFluorometer for clinical use2015-12-02Product approval · Class 1체외 제신 15-469 호
- MFDSMicrobial susceptibility testing analyzer2015-10-16Product approval · Class 1체외 제신 15-261 호
- MFDSMicrobial susceptibility testing analyzerRevoked2015-06-02Product approval · Class 1서울 체외 제신 15-195 호
- MFDSFluorometer for clinical useRevoked2014-09-03Product approval · Class 1서울 체외 제신 14-347 호
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Blood culture-free ultra-rapid antimicrobial susceptibility testing.
Nature · 2024-08 · Kim TH, Kang J, Jang H 외 17
- QMAC-DST for Rapid Detection of Drug Resistance in Pulmonary Tuberculosis Patients: A Multicenter Pre-Post Comparative Study.
Journal of clinical medicine · 2024-05 · Kwak N, Lee S, Kim S 외 9
- The QPLEX™ Plus Assay Kit for the Early Clinical Diagnosis of Alzheimer's Disease.
International journal of molecular sciences · 2023-07 · Na H, Shin KY, Lee D 외 6
- Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19.
Frontiers in immunology · 2023-01 · Lee CM, Kim M, Kang CK 외 8
- Accurate Diagnosis of COVID-19 from Self-Collectable Biospecimens Using Synthetic Apolipoprotein H Peptide-Coated Nanoparticle Assay.
Analytical chemistry · 2022-12 · Kang J, Jang H, Kim TH 외 16
- One-step assembly of barcoded planar microparticles for efficient readout of multiplexed immunoassay.
Lab on a chip · 2022-05 · Bae S, Lee D, Na H 외 2
- Application of QPLEXTM biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition.
Experimental & molecular medicine · 2022-01 · Lee D, Park JC, Jung KS 외 11
- Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture.
Applied microbiology and biotechnology · 2021-08 · Kim H, Lee S, Jo E 외 5
- The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit.
Experimental & molecular medicine · 2021-06 · Kim HJ, Park JC, Jung KS 외 11
- Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition.
Alzheimer's research & therapy · 2021-01 · Park JC, Jung KS, Kim J 외 10
Show 14 more publications
- A high-throughput cell culture system based on capillary and centrifugal actions for rapid antimicrobial susceptibility testing.
Lab on a chip · 2020-12 · Lim T, Kim EG, Choi J 외 1
- A fidget spinner for the point-of-care diagnosis of urinary tract infection.
Nature biomedical engineering · 2020-06 · Michael I, Kim D, Gulenko O 외 9
- Prospective evaluation of a rapid antimicrobial susceptibility test (QMAC-dRAST) for selecting optimal targeted antibiotics in positive blood culture.
The Journal of antimicrobial chemotherapy · 2019-08 · Kim JH, Kim TS, Jung HG 외 14
- Clinical Validation of the QMAC-DST System for Testing the Drug Susceptibility of Mycobacterium tuberculosis to First- and Second-Line Drugs.
Frontiers in microbiology · 2019-01 · Lee S, Chu D, Choi YM 외 11
- A rapid culture system uninfluenced by an inoculum effect increases reliability and convenience for drug susceptibility testing of Mycobacterium tuberculosis.
Scientific reports · 2018-06 · Jung YG, Kim H, Lee S 외 11
- ELIPatch, a thumbnail-size patch with immunospot array for multiplexed protein detection from human skin surface.
Biomicrofluidics · 2018-05 · Oh DY, Na H, Song SW 외 7
- Direct rapid antibiotic susceptibility test (dRAST) for blood culture and its potential usefulness in clinical practice.
Journal of medical microbiology · 2018-03 · Kim JH, Kim TS, Song SH 외 14
- An encoded viral micropatch for multiplex cell-based assays through localized gene delivery.
Lab on a chip · 2017-07 · Han S, Bae HJ, Kim SD 외 2
- Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis.
Scientific reports · 2017-04 · Choi J, Jeong HY, Lee GY 외 11
- Antituberculosis Activity of a Naturally Occurring Flavonoid, Isorhamnetin.
Journal of natural products · 2016-04 · Jnawali HN, Jeon D, Jeong MC 외 8
- Rapid drug susceptibility test of Mycobacterium tuberculosis using microscopic time-lapse imaging in an agarose matrix.
Applied microbiology and biotechnology · 2016-03 · Choi J, Yoo J, Kim KJ 외 11
- Fiber composite slices for multiplexed immunoassays.
Biomicrofluidics · 2015-07 · Kim J, Bae S, Song S 외 2
- Embedded biofilm, a new biofilm model based on the embedded growth of bacteria.
Applied and environmental microbiology · 2015-01 · Jung YG, Choi J, Kim SK 외 2
- A rapid antimicrobial susceptibility test based on single-cell morphological analysis.
Science translational medicine · 2014-12 · Choi J, Yoo J, Lee M 외 10
Patents
KIPRIS · applicant-matchedPublished · 2024-03 · Application 1020240042910
Published · 2023-11 · Application 1020230165265
Registered · 2023-02 · Application 1020230016317
Registered · 2022-11 · Application 1020220163717
Registered · 2022-11 · Application 1020220163654
Registered · 2020-10 · Application 1020200141017
Withdrawn · 2020-10 · Application 1020200127930
Registered · 2020-04 · Application 1020200040669
Registered · 2020-03 · Application 1020200032125
Registered · 2020-03 · Application 1020200032132
Show 18 more patents
Registered · 2020-03 · Application 1020200028427
Registered · 2020-03 · Application 1020200028512
Registered · 2017-09 · Application 1020170127094
Registered · 2017-05 · Application 1020170066636
Rejected · 2016-12 · Application 1020160170606
Registered · 2016-11 · Application 1020160146903
Registered · 2016-10 · Application 1020160136404
Registered · 2016-04 · Application 1020160048829
Registered · 2015-11 · Application 1020150164665
Registered · 2015-10 · Application 1020150146206
Registered · 2015-10 · Application 1020150146205
Registered · 2015-02 · Application 1020150021826
Registered · 2014-10 · Application 1020140139700
Registered · 2014-10 · Application 1020140138535
Registered · 2014-05 · Application 1020140053582
Registered · 2013-04 · Application 1020130043014
Registered · 2012-10 · Application 1020120115938
Registered · 2012-07 · Application 1020120073974
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot52
- PerplexityPerplexityBot5
- GoogleGoogleOther5
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for QuantaMatrix Incorporated and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsMedical Devices
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
KOSDAQ-listed in-vitro diagnostics company selling PROTIA Allergy-Q allergy diagnostic products domestically and in 80+ countries.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
Synergy Innovation, founded in 1998 and KOSDAQ-listed in 2004, manufactures and sells microbial culture media.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition